Intellipharmaceutics International Inc. (IPCIF)

OTCMKTS: IPCIF · Delayed Price · USD
0.0965
-0.0125 (-11.47%)
Jun 24, 2022 4:00 PM - Market closed
-11.47%
Market Cap 3.19M
Revenue (ttm) 176,838
Net Income (ttm) -5.10M
Shares Out 33.09M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 295
Open 0.0965
Previous Close 0.1090
Day's Range 0.0965 - 0.0965
52-Week Range 0.0800 - 0.3000
Beta 1.23
Analysts Sell
Price Target n/a
Earnings Date n/a

About IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for... [Read more...]

Industry Pharmaceuticals
Founded 1998
CEO Isa Odidi
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol IPCIF
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
0
Analyst Consensus: Sell
Stock Forecasts

News

Intellipharmaceutics Reports Director Election Results

TORONTO, ON / ACCESSWIRE / May 27, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resea...

Intellipharmaceutics Announces First Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...

Intellipharmaceutics Announces Fiscal Year 2021 Results

TORONTO, ON / ACCESSWIRE / February 28, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...

Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead

TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...

Intellipharmaceutics Comments on Recent Trading Activity

TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...

Intellipharmaceutics Announces Third Quarter 2021 Results

TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...

Kim Spencer McPhee Barristers, P.C. Publishes This Notice of Certification and Notice of Hearing for Settlement Appro...

TORONTO--(BUSINESS WIRE)--Kim Spencer McPhee Barristers, P.C. today announces a proposed securities class action settlement regarding Intellipharmaceutics International Inc. (“IPCI”). In 2019, a propose...

Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...

Intellipharmaceutics Announces First Quarter 2021 Results

TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resear...

Intellipharmaceutics Announces Fiscal Year 2020 Results

TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...